Qingdao firm that runs sales, marketing and distribution of branded medicines and supplements, including Dicare calcium, for brand owners.
Qingdao firm that runs sales, marketing and distribution of branded medicines and supplements, including Dicare calcium, for brand owners.
Is mainly paid to build and run brands rather than to make drugs, handling consumer education, doctor outreach, marketing and distribution for medicines and supplements such as the Dicare calcium line. Wholesale distribution and pharmacies add volume at lower returns, and it is deliberately trimming wholesale. Investments in innovative-drug developers are a newer thread.
Moat: narrow (distribution, brand). Hospital and pharmacy channel reach plus long-run consumer brands such as Dicare; depends on partners renewing brand rights.
Headquarters: Qingdao, China · Employees: 3,498
Size Qingdao Baheal Medical (301015.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.81B, the 1274th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.22 on 18 Nov 2026.
Performance Over six months the shares gained 1.7%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 6.2% over the last twelve months (peer median +6.7%); the operating margin is 7.8% (peer median 9.9%).
Valuation It trades at 21.0× forward earnings against a peer median of 19.1× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points above its cost of capital (6.4% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥7.10B | CN¥7.47B | CN¥8.06B | CN¥8.22B | CN¥7.48B |
| Revenue growth | — | -7% | -2% | +10% | — |
| Gross profit | CN¥2.80B | CN¥2.71B | CN¥2.79B | CN¥2.66B | CN¥2.01B |
| EBITDA | n/a | CN¥854M | CN¥1.07B | CN¥1.13B | CN¥773M |
| Net income | CN¥238M | CN¥475M | CN¥692M | CN¥712M | CN¥507M |
| Free cash flow | CN¥296M | CN¥653M | CN¥518M | CN¥619M | CN¥204M |
| Capital expenditure | CN¥219M | CN¥289M | CN¥304M | CN¥185M | CN¥105M |
| Total debt | CN¥4.11B | CN¥3.86B | CN¥2.80B | CN¥1.80B | CN¥1.77B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Qingdao Baheal Medical 301015.SZ | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% |
| Sinopharm 1099.HK | $6.74B | 0% | +3% | 3% | 6.2× | -7.3% |
| Shanghai Pharmaceuticals 601607.SS | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% |
| Jointown Pharmaceutical 600998.SS | $3.99B | +7% | +9% | 2% | 11.8× | 0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301015.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | -1.0% | 6th highest of 21 |
| 6-month return | +1.7% | -10.4% | 8th highest of 21 |
| Distance from 52-week high | -19.3% | -33.7% | 5th highest of 21 |
| Revenue growth (TTM) | -6.2% | +6.7% | 5th lowest of 21 |
| Operating margin | 7.8% | 9.9% | 11th highest of 21 |
| Forward P/E | 21.0× | 19.1× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 10.1% | 3.3% | 6th most demanding of 15 |
| Growth delivered (Del g) | +5.0% | +8.1% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | +5.1 pp | -9.0 pp | 4th most demanding of 15 |
| ROIC minus cost of capital | +3.4 pp | -0.5 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |